Vir Biotechnology (VIR) delivered earnings and revenue surprises of -67.14% and -96.59%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Canadian Business on MSN
How I Created a Plant-Based Solution to Replace Plastic
In 2018, Nuha Siddiqui turned a university project into erthos, a company creating compostable alternatives to plastics on a global scale ...
WCNC-TV Charlotte on MSN
Tom Brady reveals that he cloned his beloved dog
Retired NFL star Tom Brady said he worked with biotech firm Colossal Biosciences to clone his beloved dog. Here's a closer ...
The growing number of clinical trials, increasing regulatory complexity, and rapid AI integration in the life sciences sector are driving a radical change in the process of creating and managing ...
Bionova Scientific announced Thursday it would bring 200 new jobs to The Woodlands over the next several years, bolstering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback